Table 1.
Incidences and multiplicities of colonic lesions in all groups (18-week experiment).
| Group No. | Treatment | No. of Mice Examined | Mucosal Ulcer | High-Grade Dysplasia | Adenoma (AD) | Adeno-Carcinoma (ADC) | Total Tumor (AD+ADC) |
|---|---|---|---|---|---|---|---|
| 1 | AOM + DSS | 20 | 10/20 (50%) | 15/20 (75%) | 11/20 (55%) | 11/20 (55%) | 13/20 (65%) |
| 1.87 ± 1.81 a | 3.93 ± 2.43 | 2.40 ± 2.35 | 2.73 ± 3.45 | 5.13 ± 4.93 | |||
| 2 | AOM + DSS + 500 ppm terfenadine | 20 | 10/20 (50%) | 13/20 (65%) | 10/20 (50%) | 13/20 (65%) | 14/20 (70%) |
| 1.14 ± 0.95 | 3.29 ± 2.37 | 1.50 ± 1.70 | 2.50 ± 1.34 | 4.00 ± 2.11 | |||
| 3 | AOM + DSS + 500 ppm cimetidine | 20 | 6/20 (30%) | 11/20 (55%) | 6/20 (30%) | 5/20 (25%) | 8/20 (40%) |
| 0.53 ± 0.74 b | 1.13 ± 1.13 c | 0.53 ± 0.74 b | 0.60 ± 1.12 b | 1.13 ± 1.73 c | |||
| 4 | AOM + DSS + 10 ppm clobenpropit | 20 | 8/20 (40%) | 13/20 (65%) | 7/20 (35%) | 6/20 (30%) | 8/20 (40%) |
| 0.60 ± 0.63 b | 1.67 ± 1.29 b | 0.73 ± 0.96 b | 0.60 ± 0.91 b | 1.33 ± 1.72 c | |||
| 5 | 500 ppm terfenadine | 8 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| 6 | 500 ppm cimetidine | 8 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| 7 | 10 ppm clobenpropit | 8 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| 8 | None | 8 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
a Mean ± SD; b-d Significantly different from group 1 by one-way ANOVA followed by Tukey-Kramer test (b p < 0.01 and c p < 0.001).